Stay updated on Masitinib Efficacy and Safety in ALS Clinical Trial
Sign up to get notified when there's something new on the Masitinib Efficacy and Safety in ALS Clinical Trial page.

Latest updates to the Masitinib Efficacy and Safety in ALS Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed information about a Phase 3 study on masitinib for treating Amyotrophic Lateral Sclerosis (ALS) and the deletion of the principal investigator's name, Albert Ludolph. Additionally, the revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference17%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe page has updated the status of a project from 'Recruiting' to 'Unknown status' and has revised the version number from v2.14.2 to v2.14.3.SummaryDifference0.8%
- Check44 days agoChange DetectedDifference0.2%
- Check66 days agoChange DetectedDifference0.2%
Stay in the know with updates to Masitinib Efficacy and Safety in ALS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Masitinib Efficacy and Safety in ALS Clinical Trial page.